Payment overview · 2025
General Payments
$55.13
3 reported records · 2 companies
Healthcare provider profile · identity verified
Terri Hunt Amos, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · BOWLING GREEN, KY · NPI 1104887314
Verified facts
What the public records show
CMS Open Payments records show Terri Hunt Amos, ARNP received $55.13 in general payments during 2025 across 3 reported records.
PFIZER INC. accounted for 71.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Paxlovid.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.23 | 71.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.90 | 28.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $55.13 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.16 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 117 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 55 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
69 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
117 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 802 | 238 |
| Amlodipine Besylate | Amlodipine Besylate | 504 | 159 |
| Levothyroxine Sodium | Levothyroxine Sodium | 500 | 147 |
| Lisinopril | Lisinopril | 447 | 146 |
| Omeprazole | Omeprazole | 400 | 123 |
| Metformin Hcl | Metformin Hcl | 358 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 90 |
| Furosemide | Furosemide | 251 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 244 | 88 |
| Trazodone Hcl | Trazodone Hcl | 215 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 72 |
| Meloxicam | Meloxicam | 206 | 64 |
| Losartan Potassium | Losartan Potassium | 201 | 70 |
| Sertraline Hcl | Sertraline Hcl | 197 | 63 |
| Diclofenac Sodium | Diclofenac Sodium | 191 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 58 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 180 | 55 |
| Fluoxetine Hcl | Fluoxetine Hcl | 178 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 55 |
| Simvastatin | Simvastatin | 154 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 59 |
| Glimepiride | Glimepiride | 139 | 45 |
| Alendronate Sodium | Alendronate Sodium | 129 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 125 | 30 |
| Allopurinol | Allopurinol | 124 | 41 |
| Montelukast Sodium | Montelukast Sodium | 123 | 38 |
| Gabapentin | Gabapentin | 120 | 51 |
| Prednisone | Prednisone | 119 | 93 |
| Eliquis | Apixaban | 117 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 32 |
| Famotidine | Famotidine | 105 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 44 |
| Buspirone Hcl | Buspirone Hcl | 100 | 32 |
| Potassium Chloride | Potassium Chloride | 98 | 36 |
| Carvedilol | Carvedilol | 87 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 27 |
| Synthroid | Levothyroxine Sodium | 81 | 24 |
| Trulicity | Dulaglutide | 69 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 22 |
| Warfarin Sodium | Warfarin Sodium | 66 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 18 |
| Atenolol | Atenolol | 62 | 17 |
| Spironolactone | Spironolactone | 60 | 16 |
| Ezetimibe | Ezetimibe | 59 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 19 |
| Jardiance | Empagliflozin | 55 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 16 |
| Azithromycin | Azithromycin | 52 | 47 |
| Estradiol | Estradiol | 50 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 12 |
| Celecoxib | Celecoxib | 44 | suppressed |
| Amoxicillin | Amoxicillin | 43 | 37 |
| Lovastatin | Lovastatin | 43 | 16 |
| Sucralfate | Sucralfate | 40 | 16 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Ozempic | Semaglutide | 38 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | 11 |
| Alprazolam | Alprazolam | 35 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 14 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Finasteride | Finasteride | 33 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | 13 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 14 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Diazepam | Diazepam | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Minoxidil | Minoxidil | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Probenecid-Colchicine | Probenecid/Colchicine | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $55.13 · 3 records | PFIZER INC. | ELIQUIS, JARDIANCE, NURTEC ODT, PAXLOVID | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error